2023
Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study
Faridi K, Strom J, Kundi H, Butala N, Curtis J, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky E, Yeh R. Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study. Journal Of The American Heart Association 2023, 12: e029588. PMID: 37449567, PMCID: PMC10382113, DOI: 10.1161/jaha.123.029588.Peer-Reviewed Original ResearchConceptsExtended duration dual antiplatelet therapyDuration dual antiplatelet therapyNet adverse clinical eventsDual antiplatelet therapyAdverse clinical eventsPercutaneous coronary interventionCoronary interventionClinical eventsNonfrail patientsAntiplatelet therapyFrail patientsClaims dataMonths of DAPTClaims-based indexYears of ageMajor bleedingCause mortalityMultivariable adjustmentOlder patientsDAPT studyResults PatientsBackground FrailtyMyocardial infarctionClinical trialsMedicare claims
2021
Comparing Baseline Data From Registries With Trials Evidence From the CathPCI Registry and DAPT Study
Butala NM, Faridi KF, Secemsky EA, Song Y, Curtis J, Gibson CM, Brindis R, Shen C, Yeh RW. Comparing Baseline Data From Registries With Trials Evidence From the CathPCI Registry and DAPT Study. JACC Cardiovascular Interventions 2021, 14: 1386-1388. PMID: 34167685, PMCID: PMC8800637, DOI: 10.1016/j.jcin.2021.03.065.Peer-Reviewed Original ResearchMeSH KeywordsDrug Therapy, CombinationHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsRegistriesTreatment OutcomeComparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study
Faridi KF, Tamez H, Butala NM, Song Y, Shen C, Secemsky EA, Mauri L, Curtis JP, Strom JB, Yeh RW. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation Cardiovascular Quality And Outcomes 2021, 14: e006589. PMID: 33435731, PMCID: PMC7855905, DOI: 10.1161/circoutcomes.120.006589.Peer-Reviewed Original ResearchMeSH KeywordsAgedDrug Therapy, CombinationFemaleHumansMaleMedicareMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsStrokeTreatment OutcomeUnited StatesConceptsNegative predictive valuePositive predictive valueMyocardial infarctionPredictive valueDAPT studyClinical trialsAdjudicated eventsClaims dataNational Cardiovascular Data Registry CathPCI RegistryClinical events committeeTrial of patientsPercutaneous coronary interventionTrial end pointsKappa statisticsAdjudicated deathCathPCI RegistryCerebrovascular eventsCoronary interventionCumulative incidenceEvents committeeOutcome ascertainmentBilling claimsInpatient hospitalizationBleeding rateCardiovascular disease
2015
Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)®
Ghanbari H, Nallamothu BK, Wang Y, Curtis JP. Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)®. Journal Of The American Heart Association 2015, 4: e001331. PMID: 25637345, PMCID: PMC4345865, DOI: 10.1161/jaha.114.001331.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAtrial FibrillationCoronary Artery DiseaseDefibrillators, ImplantableDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansIncidenceMaleMedicareMiddle AgedPatient DischargePlatelet Aggregation InhibitorsRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesWarfarinConceptsImplantable cardioverter defibrillator implantationCardioverter-defibrillator implantationCoronary artery diseaseMajor adverse cardiovascular eventsNational Cardiovascular Data RegistryAdverse cardiovascular eventsDevice-related complicationsAntithrombotic agentsDefibrillator implantationArtery diseaseAtrial fibrillationAntithrombotic therapyBleeding riskCardiovascular eventsThromboembolic eventsNational Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryImplantable Cardioverter-Defibrillator RegistryHigh bleeding riskCombination of DAHospital dischargeICD implantationPrimary outcomeData registryPatientsFibrillation
2004
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB, Investigators A. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). The American Journal Of Cardiology 2004, 94: 279-283. PMID: 15276088, DOI: 10.1016/j.amjcard.2004.04.019.Peer-Reviewed Original ResearchMeSH KeywordsAgedConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPartial Thromboplastin TimeProbabilityRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival RateTenecteplaseThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsWeight-adjusted heparinST-elevation myocardial infarctionASSENT-3Myocardial infarctionASSENT-2Major bleedingIntracranial hemorrhageSmall doseFull-dose tenecteplaseLess major bleedingNew thrombolytic regimenOutcomes of patientsAcute myocardial infarctionPartial thromboplastin timeSimilar ratesRefractory ischemiaThrombolytic regimenRecurrent infarctionBaseline characteristicsHemorrhagic complicationsUnfractionated heparinThromboplastin timePatientsInfarctionTenecteplase
2003
Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study
Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. The BMJ 2003, 327: 1322. PMID: 14656840, PMCID: PMC286319, DOI: 10.1136/bmj.327.7427.1322.Peer-Reviewed Original Research